Multiple Electrolytes pH 5.5

Manufacturer
Fresenius Kabi USA, LLC | Fresenius Kabi Deutschland GmbH
Effective date
2022-11-10
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:45:08

Label at a glance#

ProductMultiple Electrolytes pH 5.5
Active ingredientSODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE
Label structure16 sections

Indications and uses

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is indicated as a source of water and electrolytes or as an alkalinizing agent.

Dosage and administration

Important Administration Instructions Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is intended for intravenous administration using sterile equipment. Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. Use a...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

FigureFigure

DESCRIPTION

DESCRIPTION SECTION

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration. Each 100 mL contains 526 mg of Sodium Chloride, USP (NaCl); 502 mg of Sodium Gluconate (C6H11NaO7); 368 mg of Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 37 mg of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is adjusted with hydrochloric acid. The pH is 5.5 (4.0 to 8.0).

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq gluconate. The osmolarity is 294 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. The caloric content is 21 kcal/L.

The flexible plastic container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers (free flex ® bag). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 has value as a source of water and electrolytes. It is capable of inducing diuresis depending on the clinical condition of the patient.

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 produces a metabolic alkalinizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is indicated as a source of water and electrolytes or as an alkalinizing agent.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is contraindicated in patients with a known hypersensitivity to the product. See WARNINGS.

WARNINGS

WARNINGS SECTION

Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Hypersensitivity and infusion reactions have been reported with Multiple Electrolytes Injection, Type 1, USP. See ADVERSE REACTIONS.

Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing. Institute appropriate therapeutic countermeasures as clinically indicated.

Electrolyte Imbalances

SPL UNCLASSIFIED SECTION

Fluid Overload

Depending on the volume and rate of infusion, the intravenous administration of Multiple Electrolytes Injection, Type 1, USP can cause electrolyte disturbances such as overhydration and congested states, including pulmonary congestion and edema.

Avoid Multiple Electrolytes Injection, Type 1, USP in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during prolonged use.

Hyponatremia

Multiple Electrolytes Injection, Type 1, USP may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.

The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of hypotonic Multiple Electrolytes Injection, Type 1, USP.

Avoid Multiple Electrolytes Injection, Type 1, USP in hypervolemic or overhydrated patients. If use cannot be avoided, monitor serum sodium concentrations.

Hypernatremia

Hypernatremia may occur with Multiple Electrolytes Injection, Type 1, USP. Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.

Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see PRECAUTIONS.

Avoid Multiple Electrolytes Injection, Type 1, USP in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor serum sodium concentrations.

Hypermagnesemia

Avoid solutions containing magnesium, including Multiple Electrolytes Injection, Type 1, USP in patients with or predisposed to hypermagnesemia, including patients with severe renal impairment and those patients receiving magnesium therapy (e.g., treatment of eclampsia and myasthenia gravis).

Multiple Electrolytes Injection, Type 1, USP is not indicated for the treatment of hypomagnesemia.

Acidosis

Multiple Electrolytes Injection, Type 1, USP is not for use for the treatment of lactic acidosis or severe metabolic acidosis in patients with severe liver and/or renal impairment.

Alkalosis

Excess administration of Multiple Electrolytes Injection, Type 1, USP can result in metabolic alkalosis. Avoid Multiple Electrolytes Injection, Type 1, USP in patients with alkalosis or at risk for alkalosis.

Multiple Electrolytes Injection, Type 1, USP is not indicated for the treatment of hypochloremic hypokalemic alkalosis. Avoid use in patients with hypochloremic hypokalemic alkalosis.

Hypocalcemia

Multiple Electrolytes Injection, Type 1, USP contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not-protein bound) calcium. Avoid Multiple Electrolytes Injection, Type 1, USP in patients with hypocalcemia.

Hyperkalemia

Potassium-containing solutions, including Multiple Electrolytes Injection, Type 1, USP may increase the risk of hyperkalemia.

Patient's at increased risk of developing hyperkalemia include those:

  • With conditions predisposing to hyperkalemia and/or associated with increased sensitivity to potassium, such as patients with severe renal impairment, acute dehydration, extensive tissue injury or burns, certain cardiac disorders such as congestive heart failure.
  • Treated concurrently or recently with agents or products that cause or increase the risk of hyperkalemia (see PRECAUTIONS).

Avoid Multiple Electrolytes Injection, Type 1, USP in patients with, or at risk for hyperkalemia If use cannot be avoided, monitor serum potassium concentrations.

Although Multiple Electrolytes Injection, Type 1, USP has a potassium concentration similar to the concentration in plasma, it is insufficient to produce a useful effect in case of severe potassium deficiency; therefore, it is not indicated for correction of severe potassium deficiency.

PRECAUTIONS

PRECAUTIONS SECTION

Patients with Renal Impairment

RENAL IMPAIRMENT SUBSECTION

In patients with renal impairment, administration of Multiple Electrolytes Injection, Type 1, USP may result in sodium and/or potassium or magnesium retention (see WARNINGS). Avoid Multiple Electrolytes Injection, Type 1, USP in patients with severe renal impairment or conditions that may cause sodium and/or potassium retention or magnesium retention, fluid overload, or edema. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.

Drug Interactions

DRUG INTERACTIONS SECTION

Other Products that Affect Fluid and/or Electrolyte Balance

Administration of Multiple Electrolytes Injection, Type 1, USP to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload. Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving such products, such as corticosteroids or corticotropin. If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance.

Other Drugs that Increase the Risk of Hyponatremia

Administration of Multiple Electrolytes Injection, Type 1, USP in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia.

Avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations.

Lithium

Renal clearance of lithium may be increased during administration of Multiple Electrolytes Injection, Type 1, USP. Monitor serum lithium concentrations during concomitant use.

Other Products that Increase the Risk of Hyperkalemia

Because of its potassium content, avoid use of Multiple Electrolytes Injection, Type 1, USP in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations.

Drugs with pH Dependent Renal Elimination

Due to its alkalinizing effect (formation of bicarbonate), Multiple Electrolytes Injection, Type 1, USP may interfere with the elimination of drugs with pH dependent renal elimination. Renal clearance of acidic drugs may be increased. Renal clearance of alkaline drugs may be decreased.

Drug/Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions. These patients were subsequently found to be free of Aspergillus infection. Therefore, positive test results for this test in patients receiving gluconate containing Multiple Electrolytes Injection, Type 1, USP solutions should be interpreted cautiously and confirmed by other diagnostic methods.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies with Multiple Electrolytes Injection, Type 1, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with Multiple Electrolytes Injection, Type 1, USP. It is also not known whether Multiple Electrolytes Injection, Type 1, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Multiple Electrolytes Injection, Type 1, USP should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known where this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Multiple Electrolytes Injection, Type 1, USP is administered to a nursing mother.

Pediatric Use

PEDIATRIC USE SECTION

The use of Multiple Electrolytes Injection, Type 1, USP in pediatric patients is based on clinical practice.

Geriatric Use

GERIATRIC USE SECTION

Geriatric patients are at increased risk of developing electrolyte imbalances. Multiple Electrolytes Injection, Type 1, USP is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Post-marketing Adverse Reactions

SPL UNCLASSIFIED SECTION

The following adverse reactions associated with the use of Multiple Electrolytes Injection, Type 1, USP were identified in clinical trials or postmarketing reports. Because postmarketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.

Hypersensitivity and Infusion Reactions: tachycardia, palpitations, chest pain, chest discomfort, dyspnea, flushing, hyperemia, asthenia, feeling abnormal, piloerection, edema peripheral, pyrexia, hypotension, wheezing, urticaria, cold sweat, chills.

General Disorders and Administration Site Conditions: infusion site pain, burning sensation.

Metabolism and nutrition disorders: hyperkalemia, hyponatremia.

Nervous System Disorders: hyponatremic encephalopathy.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Excessive administration of Multiple Electrolytes Injection, Type 1, USP, pH 5.5 can cause:

  • fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired.
  • hypernatremia and hyperkalemia, especially in patients with severe renal impairment.
  • hypermagnesemia. See WARNINGS and ADVERSE REACTIONS
  • metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations.

When assessing an overdose, any additives in the solution must also be considered.

The effects of an overdose may require immediate medical attention and treatment.

Interventions include discontinuation of Multiple Electrolytes Injection, Type 1, USP, pH 5.5, dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Important Administration Instructions

  • Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is intended for intravenous administration using sterile equipment.
  • Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.
  • Set the vent to the closed position on a vented intravenous administration set to prevent air embolism.
  • Use a dedicated line without any connections to avoid air embolism.
  • Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container.
  • Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged.
  • Multiple Electrolytes Injection, Type 1, USP, pH 5.5 is compatible with blood or blood components. It may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. Multiple Electrolytes Injection, Type 1, USP, pH 5.5 and 0.9% Sodium Chloride Injection, USP are equally compatible with blood or blood components.

Dosing Information

The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.

Introduction of Additives

Additives may be incompatible.

Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available.

If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.

HOW SUPPLIED

HOW SUPPLIED SECTION

Multiple Electrolytes Injection, Type 1, USP, pH 5.5 in free flex ® plastic containers is available as shown below:

Product CodeUnit of UseUnit of Sale
387150 NDC 65219-387-00
One 500 mL free flex ® Bag
NDC 65219-387-05
Package of 20 free flex ® Bags
387100 NDC 65219-387-02
One 1000 mL free flex ® Bag
NDC 65219-387-10
Package of 10 free flex ® Bags

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Brief exposure up to 40°C does not adversely affect the product.

The container closure is not made with natural rubber latex. Non-PVC, Non-DEHP, Sterile.

INSTRUCTIONS FOR USE

INSTRUCTIONS FOR USE SECTION

For Information on Risk of Air Embolism – see DOSAGE AND ADMINISTRATION.

Check solution container composition, lot number, and expiry date.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not use solution containers in series connections.

Do not remove solution container from its overwrap until immediately before use.

The intact port caps provide visual tamper evidence. Do not use if a port cap is prematurely removed. Maintain strict aseptic technique during handling.

TO OPEN

  1. Always inspect the solution container before and after removal from the overwrap.
  2. Place the solution container on a clean, flat surface. Using the pre-cut corner tabs, peel open the overwrap and remove the solution container from the overwrap.
  3. Check the solution container for leaks by squeezing firmly. If leaks are found, discard as sterility may be impaired.
  4. Do not use if the solution is cloudy or a precipitate is present.

TO PREPARE FOR ADMINISTRATION

  1. Immediately before inserting the infusion set, break off BLUE Infusion Port Cap with the arrow pointing away from the solution container.
  2. Use a non-vented infusion set or close the air-inlet on a vented set.
  3. Close the roller clamp of the infusion set.
  4. Hold the base of BLUE Infusion Port, twist and push the spike until the spike is fully inserted. Refer to complete directions accompanying set.
  5. The BLUE infusion port contains a self‐sealing septum that helps prevent leakage after removing the spike. The infusion port is not intended to be spiked more than once.
  6. Suspend solution container from hanger hole.

If supplemental medication is desired, follow directions below.

TO ADD MEDICATION BEFORE SOLUTION ADMINISTRATION

  1. Identify WHITE Injection Port with arrow pointing toward solution container.
  2. Immediately before injecting additives, break off WHITE Injection Port Cap with the arrow pointing toward solution container.
  3. Hold base of WHITE Injection Port.
  4. Insert needle (18 to 23 gauge) through the center of WHITE Injection Port's septum and inject additives.
  5. Mix solution container contents thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

TO ADD MEDICATION DURING SOLUTION ADMINISTRATION

  1. Close the clamp on the set.
  2. Identify WHITE Injection Port with arrow pointing toward solution container.
  3. Immediately before injecting additives, break off WHITE Injection Port cap with the arrow pointing toward solution container.
  4. Hold base of WHITE Injection Port.
  5. Insert needle (18 to 23 gauge) through the center of WHITE Injection Port's septum and inject additives.
  6. Remove container from IV pole and/or turn to an upright position.
  7. Evacuate both ports by squeezing them while container is in the upright position.
  8. Mix solution container contents thoroughly.
  9. Return container to in use position and continue administration.

For Single Use Only. Discard unused portion.

Manufactured for:

Fresenius Kabi LogoFresenius Kabi Logo

Lake Zurich, IL 60047

Made in Germany

451766

www.fresenius-kabi.com/us

Issued: September 2022

PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

500 mL

NDC 65219-387-00
Multiple Electrolytes Injection, Type 1, USP pH 5.5

Rx only

Each 100 mL contains: 526 mg Sodium Chloride, USP; 502 mg Sodium Gluconate, USP; 368 mg Sodium Acetate Trihydrate, USP; 37 mg Potassium Chloride, USP; 30 mg Magnesium Chloride, USP

pH adjusted with Hydrochloric acid.

Electrolytes per 1,000 mL: Sodium 140 mEq; Potassium 5 mEq;

Magnesium 3 mEq; Chloride 98 mEq; Acetate 27 mEq; Gluconate

23 mEq

294 mOsmol/Liter (Calc.)         pH 5.5 (4.0 to 8.0)

PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Bag Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Bag Label

PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Shipper Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 65219-387-05       387150

Multiple Electrolytes Injection, Type 1, USP pH 5.5

500 mL x 20

STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] until ready to use. Avoid excessive heat.

PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Shipper Label
PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 500 mL Shipper Label

PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Bag Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

1000 mL

NDC 65219-387-02
Multiple Electrolytes Injection, Type 1, USP pH 5.5

Rx only

Each 100 mL contains: 526 mg Sodium Chloride, USP; 502 mg Sodium Gluconate, USP; 368 mg Sodium Acetate Trihydrate, USP; 37 mg Potassium Chloride, USP; 30 mg Magnesium Chloride, USP

pH adjusted with Hydrochloric acid.

Electrolytes per 1,000 mL: Sodium 140 mEq; Potassium 5 mEq; Magnesium 3 mEq; Chloride 98 mEq; Acetate 27 mEq; Gluconate 23 mEq

294 mOsmol/Liter (Calc.)         pH 5.5 (4.0 to 8.0)

PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Bag Label
PACKAGE LABEL - PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Bag Label

PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Shipper Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 65219-387-10       387100

Multiple Electrolytes Injection, Type 1, USP pH 5.5

1000 mL x 10

STORE AT: 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] until ready to use. Avoid excessive heat.

PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Shipper Label
PACKAGE LABEL – PRINCIPAL DISPLAY – Multiple Electrolytes Injection, Type 1, USP pH 5.5 1000 mL Shipper Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
801109magnesium chloride 0.00148 MEQ/mL / potassium chloride 0.00497 MEQ/mL / sodium acetate 0.027 MEQ/mL / sodium chloride 0.0899 MEQ/mL / sodium gluconate 5.02 MG/mL Injectable SolutionPSN1
801109magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.00497 MEQ/ML / sodium acetate 0.027 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable SolutionSCD1
801109Magnesium Chloride 0.00148 MEQ/ML / K+ Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable SolutionSY1
801109Magnesium Chloride 0.00148 MEQ/ML / Pot Chloride 0.00497 MEQ/ML / Sodium Acetate 0.027 MEQ/ML / NaCl 0.0899 MEQ/ML / Sodium gluconate 5.02 MG/ML Injectable SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6e3c022f-0786-43f1-8857-edff89d5153fProduct name120260309
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2Product name520250304
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
efd58652-cb8f-4018-91ca-4b0eb2ff729fProduct name720240226
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
2641ccb3-721d-4fbf-9f2f-ca2f18157a62Product name320210309
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
e7e58cd3-cacb-49df-8d34-1ee335614abbProduct name120150609
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
65219-387-00Multiple Electrolytes pH 5.5500 mL in 1 BAGINJECTION, SOLUTION5001
65219-387-02Multiple Electrolytes pH 5.51000 mL in 1 BAGINJECTION, SOLUTION10001
65219-387-05Multiple Electrolytes pH 5.520 in 1 CASEINJECTION, SOLUTION201
65219-387-10Multiple Electrolytes pH 5.510 in 1 CASEINJECTION, SOLUTION101

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
65219-387MULTIPLE ELECTROLYTES PH 5.5 (SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]1Current NDC, Legacy NDC, 4 package rows20221118_cf1f5f15-d31d-4a02-8f7e-b289d5ad4b5c.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
65219-387-00ML - Milliliter65219-38712e29a76-1798-401c-b35f-43634f8f2a4112023-07-06
65219-387-02ML - Milliliter65219-387e6c525a1-b019-48c6-b8f1-c4a59b1169e212023-07-06
65219-387-05ML - Milliliter65219-387b9ec69bc-a1ab-4a8e-8f34-4caadffb214312023-07-06
65219-387-10ML - Milliliter65219-387402d40f3-2502-44b8-8533-0ae6ac0ffaf512023-07-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
65219-38765219-387-00, 65219-387-05, 65219-387-02, 65219-387-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-29

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-29c2088c7a36db…
2026-09-14 22:38:342026-08A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-2984e616aacf4f…
2026-08-18 06:07:402026-07A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-298072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTIONAP2022-06-29cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A215370-001MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.530MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100MLINJECTABLE / INJECTION2022-06-29a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A215370-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A215370-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A215370-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A215370-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A215370-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A215370-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A215370-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A215370-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A215370-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A215370-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A215370-001AP18072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A215370-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A215370-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A215370-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A215370-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A215370-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A215370-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A215370-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A215370-001AP1053a50430f4f…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A215370-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A215370-001AP1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A215370-001AP1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A215370-001AP1cb3db0bc1861…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Multiple Electrolytes pH 5.5SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE AND MAGNESIUM CHLORIDEFresenius Kabi USA, LLCcf1f5f15-d31d-4a02-8f7e-b289d5ad4b5c2022-11-10Warnings, Adverse reactionsExact identifier
ndc (package): 65219-387-00
ndc (package): 65219-387-02
ndc (package): 65219-387-10
ndc (package): 65219-387-05
ndc (product): 65219-387
ndc11 (package): 65219038705
ndc11 (package): 65219038702
ndc11 (package): 65219038700
ndc11 (package): 65219038710
spl id: 847f9b87-ebe4-4ff7-89b7-bcee26ef1f49
spl set id: cf1f5f15-d31d-4a02-8f7e-b289d5ad4b5c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.